Advanced search
Publication Cover
Infection and Drug Resistance Volume 16, 2023 - Issue
Submit an article Journal homepage
327
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Impact of Monthly Prophylactic Antibiotics Use in Patients with Recurrent Cellulitis: A 20-Year Population-Based Cohort Study in a Medical Center

Yu-Fen Huang1 Department of Pharmacy, Chi Mei Medical Center, Tainan, TaiwanView further author information
,
Hung-Jen Tang2 Division of Infectious Disease, Department of Medicine, Chi Mei Medical Center, Tainan, TaiwanView further author information
&
Hung-Lin Hsu3 Department of Emergency Medicine, Chi Mei Medical Center, Tainan, TaiwanCorrespondence[email protected]
View further author information
Pages 3819-3827 | Received 27 Mar 2023, Accepted 08 Jun 2023, Published online: 15 Jun 2023

References

  • Ong BS, Dotel R, Ngian VJJ. Recurrent cellulitis: who is at risk and how effective is antibiotic prophylaxis? Int J Gen Med. 2022;15:6561–6572. doi:10.2147/IJGM.S326459
  • Cranendonk DR, Lavrijsen APM, Prins JM, Wiersinga WJ. Cellulitis: current insights into pathophysiology and clinical management. Neth J Med. 2017;75(9):366–378.
  • Soo JK, Bicanic TA, Heenan S, Mortimer PS. Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitis. Br J Dermatol. 2008;158(6):1350–1353. doi:10.1111/j.1365-2133.2007.08423.x
  • Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316(3):325–337. doi:10.1001/jama.2016.8825
  • Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2004;2(2):89–95. doi:10.1046/j.1439-0353.2004.03028.x
  • Collazos J, De La Fuente B, Garcia A, et al. Cellulitis in adult patients: a large, multicenter, observational, prospective study of 606 episodes and analysis of the factors related to the response to treatment. PLoS One. 2018;13(9):e0204036. doi:10.1371/journal.pone.0204036
  • Brindle R, Williams OM, Barton E, Featherstone P. Assessment of antibiotic treatment of cellulitis and erysipelas: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(9):1033–1040. doi:10.1001/jamadermatol.2019.0884
  • Inghammar M, Rasmussen M, Linder A. Recurrent erysipelas – risk factors and clinical presentation. BMC Infect Dis. 2014;14:270. doi:10.1186/1471-2334-14-270
  • Cannon J, Dyer J, Carapetis J, Manning L. Epidemiology and risk factors for recurrent severe lower limb cellulitis: a longitudinal cohort study. Clin Microbiol Infect. 2018;24(10):1084–1088. doi:10.1016/j.cmi.2018.01.023
  • Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147–159. doi:10.1093/cid/ciu444
  • Vignes S, Dupuy A. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2006;20:818–822. doi:10.1111/j.1468-3083.2006.01648.x
  • Oh CC, Ko HC, Lee HY, Safdar N, Maki DG, Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis. J Infect. 2014;69(1):26–34. doi:10.1016/j.jinf.2014.02.011
  • Mason JM, Thomas KS, Crook AM, et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLoS One. 2014;9(2):e82694. doi:10.1371/journal.pone.0082694
  • Sjoblom AC, Eriksson B, Jorup-Ronstrom C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993;21(6):390–393. doi:10.1007/BF01728920
  • Chakroun M, Ben Romdhane F, Battikh R, Souki A, Bouzouaia N. Interet De La Benzathine Penicilline Dans La Prevention Des Recidives D’erysipele [Benzathine penicillin prophylaxis in recurrent erysipelas]. Med Mal Infect. 1994;24(10):894–897. French. doi:10.1016/S0399-077X(05)80579-7
  • Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695–1703. doi:10.1056/NEJMoa1206300
  • Thomas K, Crook A, Foster K, et al.; UK Dermatology Clinical Trials Network’s PATCH Trial Team. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network’s PATCH II trial. Br J Dermatol. 2012;166(1):169–178.
  • Dalal A, Eskin-Schwartz M, Mimouni D, et al. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database Syst Rev. 2017;6(6):CD009758. doi:10.1002/14651858.CD009758.pub2
  • Chen HM, Li YL, Liu YM, et al. The experience of intramuscular benzathine penicillin for prophylaxis of recurrent cellulitis: a cohort study. J Microbiol Immunol Infect. 2017;50(5):613–618. doi:10.1016/j.jmii.2015.08.008
  • Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–1260. doi:10.1086/496986
  • Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48. doi:10.1093/cid/cir301
  • Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35(1):208–210. doi:10.1128/AAC.35.1.208

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.